Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients — Stella

Home/Immunosuppression/Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

View on ClinicalTrials.gov

Recruiting

Back to Immunosuppression trials

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

Australia

Royal Adelaide Hospital, Adelaide, South Australia

Key details

Sponsor

Central Adelaide Local Health Network Incorporated

Collaborators

National Health and Medical Research Council, Australia, University of Adelaide

Enrollment target

~160 participants

Started

March 2024

Primary completion

December 2026

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.